• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 6th October 2015

Future Cases of Dementia among People Born in 2015 & the Dementia Drug Pipeline

It is estimated that one in three people born in 2015 in the UK may develop dementia, and clinical development success rates for dementia drugs are consistently lower than those for other therapy areas. A new analysis conducted by OHE’s…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
06-Oct-Chart-for-Dementia-Fig1-blog

It is estimated that one in three people born in 2015 in the UK may develop dementia, and clinical development success rates for dementia drugs are consistently lower than those for other therapy areas.

A new analysis conducted by OHE’s Dr Fraser Lewis estimates that one in three people born in 2015 in the UK will develop dementia. A second OHE analysis, conducted by Grace Marsden and Dr Jorge Mestre-Ferrandiz, looks at dementia treatments currently in clinical development, and reveals that clinical development success rates for dementia drugs are consistently lower than those for other therapy areas (a finding consistent with other similar analyses done to date).  

The estimates of future cases of dementia are a result of work commissioned by Alzheimer’s Research UK. The estimates were based on three components:

  • estimates of how many people born in 2015 will survive to a given age; 
  • age and sex specific estimates of the incidence of dementia;
  • an epidemiological model capable of measuring the flow of people between non-dementia and dementia, while mimicking overall population dynamics consistent with survival data.
Data was collected from the Office for National Statistics (ONS) and the Cognitive Function & Ageing Study (CFAS I), and an epidemiological model was built. 
The model calculated that:
  • 27% of males born in 2015 in the UK will develop dementia;
  • 37% of females born in 2015 in the UK will develop dementia;
  • 32% of people born in 2015 in the UK will develop dementia.
These estimates are based on conservative assumptions (for example that life expectancy will not improve in the future) and only consider late onset dementia, and therefore could be an underestimate of the total number of people who will get dementia.
 
Access the press release from Alzheimer’s Research UK here.
 
Read the story on the NHS choices website here.
 
Download the full OHE analysis here.
 
The research on drug development success rates was part of an R&D landscape and pipeline analysis of the dementia drug development arena. The analysis was based on clinical trial registries and a pipeline database. This work was undertaken in collaboration with a Clinical and Technical Expert Group (CTEG) chaired by Professor Lefkos Middleton, Imperial College London, in support of the Dementia Integrated Development Initiative, a global programme led by the UK Government to improve diagnosis and treatment of dementia worldwide.
 
The analysis identified approximately 2,000 trials for dementia treatments (based on the European Union Clinical Trials Register and the U.S. National Institutes of Health database (October 2014/January 2015)). Of these 2,000 trials, 129 had been suspended, withdrawn, or terminated early, but only 45% of the 129 provided a reason for this. See Figure 1 for the explanations given. 
 
Figure 1: Reasons for termination/suspension/withdrawal of trials (n=129)
Source: OHE analysis from IMS LifeCycle R&D Focus database (October/November 2014), and input from CTEG.
 
The analysis also identified 900 different products for dementia indications, 197 of which were in “active” development, and only 17 of which were marketed (based on IMS LifeCycle R&D Focus database (October/November 2014), and input from CTEG). 
 
The majority of the products in active development were classified as disease modifying (66%) rather than symptom modifying (31%), but this split did not carry through to the marketed treatments. In fact only one marketed disease modifying drug was identified; idebenone. This drug is marketed for treatment of cognitive defect within a relatively small range of countries.
 
Analysis of the dementia pipeline amongst other therapy areas showed that 4% of drugs in the discovery phase across all therapy areas have dementia listed as the lead indication. This proportion reduces to 1% at phase III, and 0.5% of those that are marketed. 
 

Phase success rate calculations revealed that dementia indications have lower success rates than other therapy areas (see Figure 2).

Figure 2: Phase success probabilities

LOA = Likelihood of approval. Calculated as the probability of being marketed from phase I.
Source: OHE analysis from IMS LifeCycle R&D Focus database (October/November 2014), and input from CTEG & Hay et al., 2014. Clinical development success rates for investigational drugs. Nature Biotechnology, 32(1), pp.40–51.
 
The likelihood of being marketed from phase 1 = 7.3% for dementia, and 15.3% for all therapy areas.
 
Access a preliminary report from the Dementia Integrated Development Initiative here.
 
Reference for OHE analysis: Marsden, G. & Mestre-Ferrandiz, J., forthcoming. Dementia: the R&D Landscape. OHE Research Report. London: Office of Health Economics.
 
 
  • Drug Development/R&D
  • Economics of Innovation
  • Innovation

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • June 2020

OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare

Read more
  • News
  • May 2020

Indication-Based Pricing: Are We All Onboard?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!